| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8647161 | Multiple Sclerosis and Related Disorders | 2018 | 27 Pages |
Abstract
Our study suggests that switching from natalizumab to fingolimod with a shorter washout of 4 weeks might reduce the risk of disease reactivation after switching.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Y. Naegelin, M. Rasenack, M. Andelova, S. Von Felten, B. Fischer-Barnicol, M. Amann, M. Mehling, L. Kappos, T. Sprenger, T. Derfuss,